2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing immune-related toxicities from checkpoint inhibitors in patients with bladder cancer.
Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing immune-related toxicities from checkpoint inhibitors in patients with bladder cancer.
According to Apolo, there are guidelines in the management of immune-related toxicities. Since some toxicities are rare, not all physicians have much experience managing them, making the guidelines a useful tool for patients with bladder cancer.